Pharmacokinetics of intravenously and intramuscularly administered cefepime in infants and children
| Autor: | C K Knupp, Michael D. Reed, Jeffrey L. Blumer, Toyoko S. Yamashita, J M Veazey |
|---|---|
| Rok vydání: | 1997 |
| Předmět: |
Male
Adolescent Cefepime Injections Intramuscular Surgical prophylaxis Route of administration Pharmacokinetics medicine Humans Pharmacology (medical) Child Antibacterial agent Pharmacology Volume of distribution business.industry Age Factors Infant Liter Cephalosporins Infectious Diseases Anesthesia Child Preschool Injections Intravenous Female Intramuscular injection business medicine.drug Research Article |
| Zdroj: | Antimicrobial agents and chemotherapy. 41(8) |
| ISSN: | 0066-4804 |
| Popis: | The pharmacokinetic characteristics of cefepime were determined after first dose (n = 35) and again under steady-state conditions (n = 31) with a group of 37 infants and children. In eight subjects, a cefepime dose given by intramuscular injection was substituted for an intravenous dose, and disposition characteristics were studied again. Study subjects ranged in age from 2.1 months to 16.4 years, and all had normal renal function. Each patient received 50 mg of cefepime/kg of body weight intravenously every 8 h, up to a total maximum individual dose of 2 g. With the exception of one study patient who received a single cefepime dose for surgical prophylaxis, the patients received cefepime for 2 to 13 days. Elimination half-life (t1/2), steady-state volume of distribution, total body clearance, and renal clearance after first dose administration averaged 1.7 h, 0.35 liter/kg, and 3.1 and 1.9 ml/min/kg, respectively. Although cefepime t1/2 and mean residence time (MRT) were slightly longer for subjects or =2 months of age. The integration of the cefepime pharmacokinetic data generated in our study with the MICs for important pathogens responsible for infections in infants and children supports the administration of a dose of 50 mg of cefepime/kg every 12 h for patients > or =2 months of age to treat infections caused by pathogens for which cefepime MICs are < or =8 mg/liter. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|